An acne management guideline was updated, which includes new considerations for isotretinoin, hormonal therapies, new topical ...

Please provide your email address to receive an email when new articles are posted on . The photopneumatic device improved acne in 66.7% of patients in this 7-week trial. Improvements were seen across ...

A look at the most common medications used in patients with acne. Casey Butrus, PharmD: Hilary, we have many different treatment options for acne, different mechanisms of action that have been around ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

Among nearly 20 different agents and treatment combinations, topical triple-agent fixed-dose combination (FDC) gel emerged as the most efficacious for moderate-to-severe acne. Researchers who ...

BRISBANE, Calif.--(BUSINESS WIRE)--Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey ...

Sagimet Biosciences shares rose after the company said it would focus on advancing development of its acne treatment in the U.S. The stock climbed 29% to $7.55 in premarket trading Monday. Through ...

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of ...